Hemab Therapeutics Financial Statements
NASDAQ: COAGHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
31.62+0.73 (+2.36%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Hemab Therapeutics has no annual income statement on file yet, so quarterly figures are shown instead.
Hemab Therapeutics revenue and earnings
Hemab Therapeutics reported a net loss of $24.1 million. Diluted earnings per share came in at -$0.80.
Summary generated from market data by MetaCap's automated system. Methodology
Hemab Therapeutics income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q? 20252025-06-30 | Q? 20252025-03-31 |
|---|---|---|---|---|
| Operating Expenses | 26.08M | 23.61M | 16.06M | 16.56M |
| Research & Development | 20.34M | 19.46M | 12.87M | 14.10M |
| Selling, General & Admin | 5.74M | 4.15M | 3.18M | 2.46M |
| Operating Income | -26.08M | -23.61M | -16.06M | -16.56M |
| Pretax Income | -24.05M | -22.68M | -12.21M | -15.50M |
| Income Tax | 97.00K | 12.00K | 4.00K | -190.00K |
| Net Income | -24.15M | -22.69M | -12.21M | -15.31M |
| Net Income growth (YoY) | — | — | — | — |
| EPS (Basic) | -0.80 | -23.98 | -12.91 | -16.18 |
| EPS (Diluted) | -0.80 | -23.98 | -12.91 | -16.18 |
| Shares Outstanding (Basic) | 30.11M | 946.00K | 946.00K | 946.00K |
| Shares Outstanding (Diluted) | 30.11M | 946.00K | 946.00K | 946.00K |
| EBITDA | -26.00M | -23.54M | -15.98M | -16.48M |
This table shows 4 quarterly periods of Hemab Therapeutics's income statement, from Q2 2026 back to Q? 2025, across 12 line items including operating expenses, research & development, selling, general & admin. Values in USD; B = billions, M = millions. Fiscal periods follow COAG's reporting calendar. What is a income statement?